






a**i - Grb3-3****ii - RFP NSH3SH2₄₀****iii - RFP SH2₄₀ CSH3****b****c**

Supplementary Figure 1: Grb3-3 associates with the Sos C-terminal tail

(a) Fluorescence resonance energy transfer (FRET) images demonstrating the interaction between Grb3-3 and Sos in HEK293T cells stably transfected with fibroblast growth factor receptor 2 (FGFR2) under conditions of serum-starvation (top panels) and stimulation with epidermal growth factor (EGF). (i) FRET following co-transfection with RFP-tagged full-length Grb3-3 and GFP-tagged Sos. (ii) FRET following co-transfection with truncated RFP-tagged Grb3-3, comprising of its N-terminal SH3 and SH2 domains, (NSH3SH2 Δ ₄₀) and GFP-tagged Sos. (iii) FRET following co-transfection with truncated RFP-tagged Grb3-3, comprising of its C-terminal SH3 and SH2 domains (SH2 Δ ₄₀CSH3), and GFP-tagged Sos. Control cells transfected with RFP alone showed no FRET (not shown). Scale bar 10 μ m. **(b)** Western-blot demonstrating binding of purified His-tagged full-length Grb3-3 and full-length Grb2 to GST-tagged proline-rich peptides derived from the Sos C-terminal tail. The domains from which each Sos peptide sequence is derived are shown at the top of the chart (PH, pleckstrin homology). A full list of tail sequences can be found in **Supplementary Table 1**. Sos9 peptide (not included in **Supplementary Table 1**) corresponds to GST alone. Red arrows are used to highlight probable interactions. An interaction between Grb2 and Grb3-3 is seen with Sos-CTail peptides -5, -6 and -8. **(c)** MST measurement of the interaction between purified full-length His tagged (i) Grb3-3 (left column) and (ii) Grb2 (right column) with Sos-CTail proline-rich peptides -5, -6 and -8. Unlabelled peptides (10nM-1mM) were titrated into a fixed concentration (100nM) of labelled Grb2 or Grb3-3. These confirm binding of Grb2 and Grb3-3 to Sos-CTail peptides -5 and -6.

GUGGUUUUUUGGCAAAAUCCCCAGAGCCAAGGCAGAAGAAAUGCUUAGCAAACAGCGGCACGA

ELAVL1

KHDRBS1

SRSF9

SRSF2

hnRNP C

hnRNP G

hnRNPA1

Tra2 alpha

MBNL1

KHDRBS1

KHDRBS3

hnRNP H1,2,3

hnRNPA1

hnRNPE2

SRSF10

ELAVL1

UGGGGCCUUUCUUAUCCGAGAGAGUGAGAGCGCUCCUGGGGACUUCUCCUCUCUGUCA

hnRNPF

ELAVL2

MBNL1

hnRNP I

hnRNP H1,2,3

TIA1

hnRNP I

hnRNP H1,2,3

hnRNPA1

hnRNPF



hnRNP H1,2,3

SRSF5

ELAVL1

Supplementary Figure 2: Location of consensus sites for splicing factors predicted to bind to *GRB2* exon 4 by SpliceAid2

An *in silico* analysis using SpliceAid2 with the sequence for *GRB2* exon 4 as input revealed a number of potential transcription factors predicted to bind *GRB2* exon 4. A majority were predicted to bind early in the exon sequence. Putative transcription factor binders are aligned against the sequence to which they were predicted to bind.

a**b**

Supplementary Figure 3: Determining the specificity of isoform-specific sensitive primers for the splice-sensitive Grb2/Grb3-3 qRT-PCR assay.

Agarose gel electrophoresis was used to determine primer specificity for the splice-sensitive Grb2/Grb3-3 qRT-PCR assay, and to ensure there was no cross-reactivity between the two primer transcripts or mis-priming of non-specific genes. **(a)** To assess the specificity of the Grb3-3 primer pair, HeLa cells were transfected with 0-5 μ g exogenous Grb3-3 cDNA prior to RNA extraction. Although endogenous Grb2 expression is recognised in HeLa cells, co-transfection with 0-2.0 μ g Grb2 was undertaken prior to RNA extraction to ensure no cross-reactivity under conditions in which Grb2 concentration is high. Grb3-3 primers were used and the PCR product run via agarose gel electrophoresis. In all samples, a single band was produced between 200 and 300 base pairs (bp) in size, corresponding to the expected amplicon size of 223bp for the Grb3-3 primers. This band was seen in all samples, including those not transfected with exogenous Grb3-3 cDNA, indicating that the primers are sensitive enough to detect endogenous levels of the Grb3-3 transcript. The PCR fragment from sample 9, corresponding to endogenous Grb3-3, was gel extracted, cloned into a TA vector and sequenced confirming that the PCR product produced was Grb3-3. **(b)** To assess the specificity of Grb2-specific primers, the Grb2 primer pair was used to generate a PCR product from RNA extracted from HeLa cells. Given the known endogenous Grb2 expression in HeLa cells, no exogenous Grb2 cDNA was transfected prior to RNA extraction. In order to ensure there was no cross-reactivity with Grb3-3, one sample was transfected with 5 μ g of Grb3-3 cDNA. A single band was produced in both samples, indicating no cross reactivity. The band observed is less than 100 base pairs in size, corresponding to the expected amplicon size for the Grb2

primers of 76bp. Sequencing of the PCR product following gel extraction confirmed that the product was Grb2 mRNA.

Figure 1a

pERK



ERK



α -Tubulin






Figure 1c


pEGFR




pERK




EGFR



ERK



α -Tubulin



Supplementary Figure 4: Uncropped and unprocessed Western blots for Figure 1.

Uncropped Western blots shown for representative Figures 1a, 1c and 1e. The blue boxes denote regions of interest shown in the representative figures.

Figure 1a: Blots were first probed for pERK and then probed for ERK and, subsequently, α -Tubulin loading control on the same blot. ERK and α -tubulin are shown on the same blot given their similar size, with α -Tubulin bands shown above ERK bands. **Figure 1c:** Blots were first probed for pEGFR and pERK and then respectively probed for EGFR and ERK. α -Tubulin loading control was probed last.

Figure 2

Sos1



RFP





Figure 3b

Sos



E-Cadherin




β -actin



Figure 4

anti-hnRNPC



anti-hnRNPC




Figure 3a

Sos1



RFP-Grb2 / RFP




Strep Grb3-3




Extended Data Figure 1


Grb2



Grb3-3



GST



Supplementary Figure 5: Uncropped and unprocessed Western blots for Figures 2, 3 and 4, as well as Supplementary Figure 1

Uncropped Western blots shown for representative **Figures 2, 3, 4** and **Supplementary Figure 1**. Blue boxes denote regions of interest shown in the representative figure.

Sos domain	Peptide name	Sequence
PH	Sos-PH-1	MICCKSNHGQ PRLP GASNAEYRLK
CDC25	Sos-CDC25-2	DHYKKYLAKLRSINP PCVP FFGIYLTNILKTE
	Sos-CDC25-3	TDYLFNKSLEIEPRNPKPL PRFPKK YSYPLKSPGVRPSNP RPGTMRHPTPLQQEP
	Sos-CDC25-4	ESETESTASA PNSPRTPLTPP ASGASSTTDVCSVFDSDH SSPFHSSNDTVFIQVTLPHGPRSASVSSISL
Proline-rich C-terminus tail	Sos-CTail-5	TKGTDEVPV PPVPPRRR ESAPAESSPSKIM
	Sos-CTail-6	SKHLDS PPAIPPRQT SKAYSPRYSISDRTSISDPPESPPL LPPREPVRTPDVFSSSP
	Sos-CTail-7	LHLQPPPLGKKSDHGNAFF PNSPSPFTPPPQTP SPHGT RRHLPSPLTQEVDLHSI
	Sos-CTail-8	EVDLHSIAG PPVPPR QSTSQH PKLPPK TYKREHTHPSMH

Supplementary Table 1: Amino acid sequences of Sos proline-rich peptides by the domain from which they are isolated. Proline-rich motifs are highlighted in red and by bold, underling type face. NB. Peptide Sos-CTail-8 contains two PXXP motifs. However, the proximity of these means that they are unlikely to sustain two individual SH3 domain binding sites.

Splicing factor	Recognised sequence	Sequence position
ELAVL1	UUUUU	5-9 or 6-10
HNRNP C	UUUUU(U) UUUUUG	5- 9 or 10 6-10
KHDRBS1	UUUUUU (CA)AAAU	5-10 13-18 or 15-18
HNRNP G	AAAAU AUCCCC	14-18 17-22
KHDRBS3	AAAU	15-18 or 39-42
HNRNP E2	UCCCA	18-23
SRSF9	AGGCA	30-34
SRSF2	AGAAG	34-38
SRSF10	(G)AAGAA	35-40 or 36-40
Tra2alpha	AAGAA	36-40
HNRNP A1	CUUAG	44-48
ELAVL2	CUUUC	70-74
TIA-1	CUUUC	70-74
MBNL1	AUGCUU GCGCUC	41-46 93-98
HNRNP F	UGGGG GGGGC UGGGG GGGGA	64-68 65-69 100-104 101-105
HNRNP H1, H2, H3	AAGAA UGGGG GGGGC AGAGA UGGGG GGGGA	36-40 64-68 65-69 82-86 100-104 101-105
HNRNP I	CUUUCUU CUCUCU UCUCU	70-76 113-118 114-118
SRSF5	ACAGC	52-56

Supplementary Table 2: Splicing factors predicted via *in silico* analysis to bind to sequences located within *GRB2* exon 4 using SpliceAid2. Around half of the identified proteins are constituents of the hnRNP family. SR proteins are also strongly represented.

<i>In-silico</i> prediction		Experimental validation (number of peptides)		
Splicing factor	RNA oligonucleotide containing binding site	Oligo 1 (1-50)	Oligo 2 (53-103)	Oligo 3 (104-123)
ELAVL1	Oligo1	11	5	3
HNRNP C	Oligo 1	10	0	1
KHDRBS1	Oligo 1	2	0	1
HNRNP G	Oligo 1	8	0	7
KHDRBS3	Oligo 1	0	0	0
HNRNP E2	Oligo 1	9	12	4
SRSF9	Oligo1	0	4	12
SRSF2	Oligo1	4	4	4
SRSF10	Oligo1	0	5	0
Tra2alpha	Oligo1	0	3	3
HNRNP A1	Oligo1	24	19	32
ELAVL2	Oligo2	0	0	0
TIA-1	Oligo2	13	2	3
MBNL1	Oligo1& 2	0	0	0
HNRNP F	Oligo2	6	0	4
HNRNPH1	Oligo1& 2	18	1	16
HNRNPH2	Oligo1& 2	11	1	8
HNRNPH3	Oligo1& 2	4	0	2
HNRNP I	Oligo 2 & 3	29	11	7
SRSF5	Oligo 2	2	0	2

Supplementary Table 3: Experimental validation of proteins binding to *GRB2* exon 4. Splicing factors predicted to bind to exon 4 of *GRB2* by SpliceAid2 are shown, as are the RNA oligonucleotide that contain the consensus binding site for each predicted splicing factor. The number of peptides corresponding to each protein that

were identified by mass spectrometry analysis of each RNA oligonucleotide is shown.

Only proteins with two or more matching peptides were considered to have bound.

Oligo/SpliceAid	hnRNP/SR proteins	
	Number	Names
Oligo1, Oligo2, Oligo3, SpliceAid2	2	SRSF2, hnRNPA1
Oligo1, Oligo2, Oligo3	10	hnRNPL, hnRNPK, hnRNPO, hnRNPU, hnRNPA2B1, hnRNPA3, hnRNPR, hnRNPAO, hnRNPAAB, hnRNPD
Oligo1, Oligo3, SpliceAid2	3	hnRNPH1, hnRNPF, hnRNPH2
Oligo2, Oligo3, SpliceAid2	1	SRSF9
Oligo1, Oligo3	8	hnRNPM, SRSF3, hnRNPD, hnRNPU, SRSF4, SRSF7, SRSF1, SRSF6
Oligo1, SpliceAid2	3	hnRNPC, SRSF5, hnRNPH3
Oligo2, SpliceAid2	1	SRSF10
Oligo1	2	hnRNPU2, hnRNPL
Oligo2	3	hnRNP H, hnRNPD0, SRSF7
SpliceAid2	3	hnRNPE2, hnRNPI, hnRNPG

Supplementary Table 4: A list of hnRNP/SR proteins identified by mass spectrometry (Oligo1, Oligo2, Oligo3) and predicted to bind by SpliceAid2.

Output type	Output
rMATS ID	27123
Gene ID	ENSG00000177885.9
Gene Name	GRB2
Chromosome	17
Gene Strand	-
Exon Start	73321978
Exon End	73322101
Upstream Exon Start	73317875
Upstream Exon End	73317908
Downstream Exon Start	73328780
Upstream Exon End	73328878
Inclusion Counts hnRNPC shRNA	198, 190
Skipping Counts hnRNPC shRNA	1, 5
Inclusion Counts Control	291, 364
Skipping Counts Control	0, 0
Length of Inclusion Form (used for normalisation)	197
Length of Skipping Form (used for normalisation)	99
P Value	0.008984227
False Discovery Rate (calculated from P value)	0.108942659
Inclusion Level for Sample 1	0.99, 0.95
Inclusion Level for Sample 2	1.0, 1.0
Inclusion Level Difference	-0.03

Supplementary Table 5: rMATs analysis of significantly different splicing events for hnRNPC knockdown and control experiments.